Stephens Inc. AR Has $953,000 Position in Haleon plc (NYSE:HLN)

Stephens Inc. AR cut its holdings in Haleon plc (NYSE:HLN) by 9.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 99,937 shares of the company’s stock after selling 10,904 shares during the quarter. Stephens Inc. AR’s holdings in Haleon were worth $953,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Fortitude Family Office LLC bought a new stake in shares of Haleon during the third quarter worth $28,000. Versant Capital Management Inc increased its position in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the period. Geneos Wealth Management Inc. acquired a new position in Haleon during the 4th quarter valued at about $35,000. Toronto Dominion Bank boosted its stake in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after purchasing an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Haleon during the 4th quarter worth approximately $39,000. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

Shares of HLN stock opened at $9.95 on Friday. The stock has a market cap of $45.02 billion, a PE ratio of 29.25, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28. The stock has a 50-day moving average of $9.54 and a 200-day moving average of $9.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a one year low of $7.89 and a one year high of $10.80.

Analysts Set New Price Targets

HLN has been the topic of several analyst reports. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Haleon currently has an average rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.